Cancer Chemotherapy and Pharmacology

Volume 12 1984

Edited by

S.K. CARTER and T. McELWAIN

Editorial Board

M. Acton Menlo Park
P. Alberto Geneva
R. H. Blum New York
M. Boiron Paris
H. Calvert Sutton
R. L. Comis Syracuse
T. Connors Carshalton
R. C. Coombes Sutton
S. Eckhardt Budapest
R. M. Fox Sydney
R. M. Fox Manchester
S. Garattini Milano
M. Ghione Milano
H. Hansen Copenhagen
K. Karrer Vienne
D. L. Kisner Bethesda
J. Laszlo Durham
R. B. Livingston Seattle
J. S. Macdonald Bethesda
J. G. McVie Amsterdam
F. M. Muggia New York
M. Ogawa Tokyo
P. Martin Marseille
S. Pavlovsky Buenos Aires
P. Potier Gif-sur-Yvette
P. Reizenstein Stockholm
E. Robinson Haifa
M. Rozencweig Brussells
C. G. Schmidt Essen
J. Smyth Edinburgh
A. Trouet Brussells
S. Tsukagoshi Tokyo
U. Umezawa Tokyo
L. M. van Putten Rijswijk
F. A. Valeriote St. Louis
P. Wilkinson Manchester
G. Wu Huan-Hsin Peking

Springer International

Cancer Chemotherapy and Pharmacology

This journal was founded in 1978. Editors: S. K. Carter, T. McElwain. Published by Springer International.

Copyright
Submission of a manuscript implies that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review or thesis), that it is not under consideration for publication elsewhere, that its publication has been approved by all the authors and by the responsible authorities – tacitly or explicitly – in the institutes where the work was carried out and that, if accepted, it will not be published elsewhere in the same form, in either the same or another language, without the consent of the copyright holders. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform, electronic data base, video disks, or any other reproductions of similar nature, and translations.

Photographic reproduction, microform electronic data base, video disks, or any other reproduction of text, figures, or tables from this journal is prohibited without permission obtained from the publisher.

The use of general descriptive names, trade names, trade marks, etc., in this publication, even if the former are not specifically identified, is not to be interpreted as exempt from the relevant protective laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for the USA

Photocopies may be made for personal or internal use beyond that permitted by Section 107 or 108 of the U.S. Copyright Law, provided a fee is paid. This fee is $ 0.20 per page or a minimum of $ 1.00 if an article consists of less than five pages. Please pay this fee to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0302-8933, volume, and first and last page numbers of each article copied.

The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying.

Other regulations

Authors of this journal can benefit from library and photocopy fees collected by VG WORT if certain conditions are met. If an author lives in the Federal Republic of Germany or in West Berlin it is recommended that he contact Verwertungsgesellschaft WORT, Abteilung Wissenschaft, Goethestraße 49, D-8000 München 2, for detailed information.

Printed in Germany by v. Starck'sche Druckereigesellschaft m.b.H., D-6200 Wiesbaden

© by Springer-Verlag Berlin Heidelberg 1984

Table of Contents

Abrams, J., see Espana, P., et al. 98
Alberts, D. S., see Ludwig, R., et al. 135
Alberts, D. S., see Ludwig, R. 142
Alison, M. R., see Benton, H. P. 53
André, F., see Martin, P. M., et al. 13
Ang, L. M., see Slevin, M. L., et al. 151
Appel, P. L., see Harris, R. N., et al. 167
Arcamone, F., Lazzati, M., Vicario, G. P., Zini, G.: Disposition of ^{14}C-labelled 4'-epidoxorubicin and doxorubicin in the rat. A comparative study 157
Arcamone, F., see Zini, G., et al. 154
Azarnia, N., see Preisler, H. D., et al. 125

Bachur, N. R., Friedman, R. D., Hollenbeck, R. G.: Physicochemical characteristics of ferric adriamycin complexes 5
Barbieri, A. De, see Yagi, M. J., et al. 70
Basseches, P. J., see Harris, R. N., et al. 167
Beaudry, J. N., see Ludwig, C. U., et al. 146
Bekesi, J. G., see Yagi, M. J., et al. 70
Bekesi, J. G., see Yagi, M. J., et al. 77
Bellanova, B., see Martoni, A., et al. 179
Benjamin, R. S., see Stewart, D. J., et al. 116
Benton, H. P., Alison, M. R.: Do cells of continually renewing populations and those stimulated from quiescence respond similarly to HU and Ara-C? 53
Benz, C., Choti, M., Newcomer, L., Cadman, E.: Thymidine enhancement of methotrexate and 5-fluorouracil toxicity in cultured human colon carcinoma 104
Billiaert, P., see Welsh, J., et al. 198
Blackie, R. G. G., see Welsh, J., et al. 198
Bolanowska, W., see Preisler, H. D., et al. 125
Bosanquet, A. G., Gilby, E. D.: Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma 183
Bozek, T., see Stuart-Harris, R. C., et al. 1
Brennan, J., see Preisler, H. D., et al. 125
Browman, G., see Preisler, H. D., et al. 125
Budd, G. T., Bukowski, R. M., Miketo, L., Yen-Lieberman, B., Proffitt, M. R.: Phase-I trial of Ultrapure™ human leukocyte interferon in human malignancy 39
Bukowski, R. M., see Budd, G. T., et al. 39
Burchenal, J., see Scher, H. I., et al. 101

Cadman, E., see Benz, C., et al. 104
Calman, K. C., see Welsh, J., et al. 198
Camaggi, C. M., see Martoni, A., et al. 179
Cano, J. P., see Lena, N., et al. 120
Caracandas, J. E., see Reddy, S. K., et al. 190
Caracassonne, Y., see Lena, N., et al. 120
Carter, S. K.: The carcinogenic potential of cytotoxic chemotherapy and its implications for therapeutic decision-making **67**
Chen, T. Y., see Reddy, S. K., et al. 190
Chervenik, P., see Preisler, H. D., et al. 125
Choti, M., see Benz, C., et al. 104
Čotard, M., see Martin, P. M., et al. 13

Daniel, M. D., see Yagi, M. J., et al. 70
D'Arrigo, P., see Preisler, H. D., et al. 125
DeGraw, J. I., see Sirotnak, F. M., et al. 18
DeGraw, J. I., see Sirotnak, F. M., et al. 26
DeGregorio, M. W., Lui, G. M., Macher, B. A., Wilbur, J. R.: Uptake, metabolism, and cytotoxicity of doxorubicin in human Ewing's sarcoma and rhabdomyosarcoma cells 59
Deurloo, J., see Nooter, K., et al. 187
Dhaliwal, H. S., see Rohatiner, A., et al. 90
Donker, A. J. M., see Offerman, J. J. G., et al. 36
Doorenbos, H., see Veelen, H. van, et al. 83
Dorato, A., see Dufour, M., et al. 94
Dufour, M., Germain, J. St., Skalski, V., Dorato, A., Lazarus, P., Panasci, L. C.: Effect of administration of sodium cyanate and melphalan on the lifespan of P388 tumor-bearing CD2F1 mice 94
Durski, A. M., see Harris, R. N., et al. 167

Early, A. P., see Preisler, H. D., et al. 125
Ehninger, G., Proksch, B., Hartmann, F., Gärtner, H. V., Wilms, K.: Mitoxantrone metabolism in the isolated perfused rat liver 50
Epstein, J., see Preisler, H. D., et al. 125
Espana, P., Smith, F., Abrams, J., Haidak, D., Ueno, W., Woolley, P., Schein, P.: Phase-II study of *cis*-diammine-dichloro platinum (*cis*-platinum), bleomycin and methotrexate for advanced squamous cell carcinoma of head and neck 98

Favre, R., see Lena, N., et al. 120
Feun, L. G., see Stewart, D. J., et al. 116
Friedman, R. D., see Bachur, N. R., et al. 5
Fujimoto, S., Wang, Y., Ogawa, M.: Antitumor activity and toxicity of ACNU, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride, comparing two divided doses and a single dose 173

Gärtner, H. V., see Ehninger, G., et al. 50
Germain, J. St., see Dufour, M., et al. 94
Gessner, T., see Preisler, H. D., et al. 125
Gilby, E. D., see Bosanquet, A. G. 183
Ginsburg, E., Gram, T. E., Trush, M. A.: A comparison of the pulmonary toxicity and chemotherapeutic activity of bleomycin-BAPP to bleomycin and pepleomycin 111
Giovannini, M., see Martoni, A., et al. 179
Goldberg, J., see Preisler, H. D., et al. 125
Gottlieb, A., see Preisler, H. D., et al. 125
Goutas, L. J., see Sirotnak, F. M., et al. 18
Goutas, L. J., see Sirotnak, F. M., et al. 26
Gralla, R., see Scher, H. I., et al. 101
Gram, T. E., see Ginsburg, E., et al. 111
Green, M. R., see Young, J. A., et al. 43
Grunwald, H., see Preisler, H. D., et al. 125

Hagenbeek, A., see Nooter, K., et al. 187
Haidak, D., see Espana, P., et al. 98
Halbert, G., see Welsh, J., et al. 198
Harris, R. N., Basseches, P. J., Appel, P. L., Durski, A. M., Powis, G.: Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: A pharmacokinetic study 167
Hartmann, F., see Ehninger, G., et al. 50
Hem, G. K. van der, see Offerman, J. J. G., et al. 36
Holland, J. F., see Yagi, M. J., et al. 70
Holland, J. F., see Yagi, M. J., et al. 77
Hollenbeck, R. G., see Bachur, N. R., et al. 5
Howell, S. B., see Young, J. A., et al. 43

Imbert, A. M., see Lena, N., et al. 120

Jahren, G., see Lønning, P. E., et al. 10
Johnston, A., see Slevin, M. L., et al. 151
Jones, L., see Scher, H. I., et al. 101
Joyce, R., see Preisler, H. D., et al. 125

Kalman, L., see Scher, H. I., et al. 101
Keating, M. J., see Stewart, D. J., et al. 116
Kelsen, D., see Scher, H. I., et al. 101
Koops, H. S., see Offerman, J. J. G., et al. 36
Kvinnsland, S., see Lønning, P. E., et al. 10

Lane, W. W., see Reddy, S. K., et al. 190
Larson, R., see Preisler, H. D., et al. 125
Lauro, L. Di., see Lopez, M., et al. 194
Lazarus, P., see Dufour, M., et al. 94
Lazzati, M., see Arcamone, F., et al. 157
Lazzati, M., see Zini, G., et al. 154
Lee, H., see Preisler, H. D., et al. 125
Lena, N., Imbert, A. M., Pignon, T., Favre, R., Meyer, G., Cano, J. P., Carcassonne, Y.: Methotrexatevindesine association in the treatment of head and neck cancer Influence of vindesine on methotrexate's pharmacokinetic behavior 120
Lennard, L., see Rees, C. A., et al. 87
Lilleyman, J. S., see Rees, C. A., et al. 87
Lister, T. A., see Rohatiner, A., et al. 90
Lister, T. A., see Rohatiner, A., et al. 90
Litterst, C. L., Schweitzer, V. G.: Increased tissue deposition and decreased excretion of platinum following administration of cisplatin to cisplatin-pretreated animals 46
Lønning, P. E., Kvinnsland, S., Jahren, G.: Aminoglutethimide and warfarin. A new important drug interaction 10
Loo, T. L., see Stewart, D. J., et al. 116
Lopez, M., Perno, C. F., Lauro, L. Di, Papaldo, P.: 5-Fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer 194
Lu, K., see Stewart, D. J., et al. 116
Ludwig, C. U., Peng, Y. M., Beaudry, J. N., Salmon, S. E.: Cytotoxicity of mitomycin C on clonogenic human carcinoma cells is not enhanced by hypoxia 146
Ludwig, R., Alberts, D. S.: Chemical and biological stability of anticancer drugs used in a human tumor clonogenic assay 142
Ludwig, R., Alberts, D. S., Miller, T. P., Salmon, S. E.: Evaluation of anticancer drug schedule dependency using an in vitro human tumor clonogenic assay 135
Lui, G. M., see DeGregorio, M. W., et al. 59
Luna, M., see Stewart, D. J., et al. 116

Macher, B. A., see DeGregorio, M. W., et al. 59
Maddocks, J. L., see Rees, C. A., et al. 87
Mahony, M. J., Murphy, M. S., Wadsworth, J., Mott, M. G.: Modification of oral methotrexate absorption in children with leukemia 131
Malpas, J. S., see Rohatiner, A., et al. 90
Martens, A., see Nooter, K., et al. 187
Martin, P. M., Čotard, M., Mialot, J.-P., André, F., Raynaud, J.-P.: Animal models for hormone-dependent human breast cancer. Relationship between steroid receptor profiles in canine and feline mammary tumors and survival rate 13
Martini, A., see Martoni, A., et al. 179
Martoni, A., Giovannini, M., Tomasi, L., Camaggi, C. M., Bellanova, B., Monetti, N., Rossini, G., Tarquinii, M., Martini, A., Pannuti, F.: A phase-II clinical trial of 4'-epi-doxorubicin in advanced solid tumors 179
Meijer, S., see Offerman, J. J. G., et al. 36
Meyer, G., see Lena, N., et al. 120
Mialot, J.-P., see Martin, P. M., et al. 13
Miketo, L., see Budd, G. T., et al. 39
Miller, K., see Preisler, H. D., et al. 125
Miller, T. P., see Ludwig, R., et al. 135
Moccio, D. M., see Sirotnak, F. M., et al. 18
Moccio, D. M., see Sirotnak, F. M., et al. 26
Monetti, N., see Martoni, A., et al. 179
Mott, M. G., see Mahony, M. J., et al. 131
Mulder, N. H., see Offerman, J. J. G., et al. 36
Murphy, M. S., see Mahony, M. J., et al. 131

Newcomer, L., see Benz, C., et al. 104
Nooter, K., Sonneveld, P., Deurloo, J., Oostrum, R., Schultz, F., Martens, A., Hagenbeek, A.: Repeated daunomycin administration in rats. Pharmacokinetics and bone marrow toxicity 187

Offerman, J. J. G., Meijer, S., Sleijfer, D. T., Mulder, N. H., Donker, A. J. M., Koops, H. S., Hem, G. K. van der: Acute effects of *cis*-diamminedichloroplatinum (CDDP) on renal function 36
Ogawa, M., see Fujimoto, S., et al. 173
Oliver, R. T. D., see Ponder, B. A. J. 64
Oostrum, R., see Nooter, K., et al. 187

Panasci, L. C., see Dufour, M., et al. 94
Pannuti, F., see Martoni, A., et al. 179
Papaldo, P., see Lopez, M., et al. 194
Pavlidis, N. A., see Stuart-Harris, R. C., et al. 1
Peng, Y. M., see Ludwig, C. U., et al. 146
Perno, C. F., see Lopez, M., et al. 194
Pignon, T., see Lena, N., et al. 120
Ponder, B. A. J., Oliver, R. T. D.: Phase II study of VP 16-213 (etoposide) in metastatic transitional cell urothelial cancer 64
Powis, G., see Harris, R. N., et al. 167
Pratt, J. J., see Veelen, H. van, et al. 83
Preisler, H. D., Gessner, T., Azarnia, N., Bolanowska, W., Epstein, J., Early, A. P., D'Arrigo, P., Vogler, R., Winton, L., Chervenik, P., Joyce, R., Lee, H., Steele, R., Goldberg, J., Gottlieb, A., Browman, G., Miller, K., Grunwald, H., Larson, R., Brennan, J.: Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia 125
Proffitt, M. R., see Budd, G. T., et al. 39
Proksch, B., see Ehninger, G., et al. 50

Raynaud, J.-P., see Martin, P. M., et al. 13
Reddy, S. K., Takita, H., Lane, W. W., Vincent, R. G., Chen, T. Y., Caracandas, J. E., Regal, A.-M.: Cyclic alternating combination chemotherapy for small cell lung cancer 190
Rees, C. A., Lennard, L., Lilleyman, J. S., Maddocks, J. L.: Disturbance of 6-mercaptopurine metabolism by cotrimoxazole in childhood lymphoblastic leukaemia 87
Regal, A.-M., see Reddy, S. K., et al. 190
Rohatiner, A., Slevin, M. L., Dhaliwal, H. S., Malpas, J. S., Lister, T. A.: High-dose cytosine arabinoside: response to therapy in acute leukaemia and non-Hodkin's lymphoma 90
Rossini, G., see Martoni, A., et al. 179

Salmon, S. E., see Ludwig, R., et al. 135
Salmon, S. E., see Ludwig, C. U., et al. 146
Samuels, L. L., see Sirotnak, F. M., et al. 18
Savaraj, N., see Stewart, D. J., et al. 116
Schein, P., see Espana, P., et al. 98
Scher, H. I., Kelsen, D., Kalman, L., Jones, L., Burchenal, J., Gralla, R.: Phase-II trial of 1,2-diaminocyclohexane (4-carboxyphthalato) platinum (II) (DACCP) in non-small cell lung cancer 101
Schmid, F. A., see Sirotnak, F. M., et al. 26
Schultz, F., see Nooter, K., et al. 187
Schweitzer, V. G., see Litterst, C. L. 46
Setanoians, A., see Welsh, J., et al. 198
Sethi, V. S., Surratt, P., Spurr, C. L.: Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys 31
Sirotnak, F. M., DeGraw, J. I., Moccio, D. M., Samuels, L. L., Goutas, L. J.: New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties 18
Sirotnak, F. M., DeGraw, J. I., Schmid, F. A., Goutas, L. J., Moccio, D. M.: New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models 26
Skalski, V., see Dufour, M., et al. 94
Sleijfer, D. T., see Offerman, J. J. G., et al. 36
Sleijfer, D. T., see Veelen, H. van, et al. 83
Slevin, M. L., Ang, L. M., Johnston, A., Turner, P.: The efficiency of protective gloves used in the handling of cytotoxic drugs 151
Slevin, M. L., see Rohatiner, A., et al. 90
Sluiter, W. J., see Veelen, H. van, et al. 83
Smith, F., see Espana, P., et al. 98
Smith, I. E., see Stuart-Harris, R. C., et al. 1
Sonneveld, P., see Nooter, K., et al. 187
Spurr, C. L., see Sethi, V. S., et al. 31
Steele, R., see Preisler, H. D., et al. 125
Stewart, D. J., Zhengang, G., Lu, K., Savaraj, N., Feun, L. G., Luna, M., Benjamin, R. S., Keating, M. J., Loo, T. L.: Human tissue distribution of 4'-(9-acridinylamino)-methanesulfon-m-aniside (NSC 141549, AMSA) 116
Stuart, J. F. B., see Welsh, J., et al. 198
Stuart-Harris, R. C., Bozek, T., Pavlidis, N. A., Smith, I. E.: Mitoxantrone: An active new agent in the treatment of advanced breast cancer 1
Surratt, P., see Sethi, V. S., et al. 31

Takita, H., see Reddy, S. K., et al. 190
Tarquinii, M., see Martoni, A., et al. 179
Tomasi, L., see Martoni, A., et al. 179
Trush, M. A., see Ginsburg, E., et al. 111
Turner, P., see Slevin, M. L., et al. 151

Ueno, W., see Espana, P., et al. 98

Veelen, H. van, Willemse, P. H. B., Sleijfer, D. T., Pratt, J. J., Sluiter, W. J., Doorenbos, H.: Adrenal suppression by oral high-dose medroxyprogesterone acetate in breast cancer patients 83
Vicario, G. P., see Arcamone, F., et al. 157
Vicario, G. P., see Zini, G., et al. 154
Vincent, R. G., see Reddy, S. K., et al. 190
Vogler, R., see Preisler, H. D., et al. 125

Wadsworth, J., see Mahony, M. J., et al. 131
Wang, Y., see Fujimoto, S., et al. 173
Welsh, J., Stuart, J. F. B., Setanoians, A., Blackie, R. G. G., Billiaert, P., Halbert, G., Calman, K. C.: The analysis and animal pharmacokinetics of 1,2,4, triglycidyl urazol using a high-pressure liquid chromatographic technique 198
Wilbur, J. R., see DeGregorio, M. W., et al. 59
Willemse, P. H. B., see Veelen, H. van, et al. 83
Wilms, K., see Ehninger, G., et al. 50
Winton, L., see Preisler, H. D., et al. 125
Woolley, P., see Espana, P., et al. 98

Yagi, M. J., Bekesi, J. G., Daniel, M. D., Holland, J. F., Barbier, A. De: Increased cancericidal activity of PTT.119, a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. I. In vitro cytotoxicity 70
Yagi, M. J., Zanjani, M., Holland, J. F., Bekesi, J. G.: Increased cancericidal activity of PTT.119, a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. II. In vivo bioassay 77
Yen-Lieberman, B., see Budd, G. T., et al. 39
Young, J. A., Howell, S. B., Green, M. R.: Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine 43

Zanjani, M., see Yagi, M. J., et al. 77
Zhengang, G., see Stewart, D. J., et al. 116
Zini, G., Vicario, G. P., Lazzati, M., Arcamone, F.: Radioactive species in rat urines and tissues after [^{14}C] AD 32 administration 154
Zini, G., see Arcamone, F., et al. 157